Drug Insights

Unveiling Fexofenadine: How to Search for it on Synapse

24 March 2024
2 min read

Approved by the FDA in March 1996, Fexofenadine is a puzzling small molecule drug that works as an H1 receptor antagonist. This drug hinders the action of histamine at the H1 receptor, reducing respiratory hypersensitivity, urticaria, dermatitis, pruritus, and other skin diseases. Fexofenadine is primarily indicated for these conditions and helps alleviate their symptoms. Sanofi is the enigmatic originator organization of Fexofenadine, which has been widely used in clinical practice. Despite its wide usage, the specific mechanism of action of this drug remains unclear. Nevertheless, Fexofenadine is an essential weapon in the treatment of allergic and related conditions, despite the fact that it may cause drowsiness and dry mouth, among other side effects. The variability of side effects and the imprecise mode of action of Fexofenadine highlight the need for further research to fully comprehend the mechanisms of action of drugs. Click on the image below to begin the exploration journey of Fexofenadine through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

23andMe Initiates Clinical Trial of Dual-Targeting Antibody 23ME-01473 Against ULBP6
Latest Hotspot
3 min read
23andMe Initiates Clinical Trial of Dual-Targeting Antibody 23ME-01473 Against ULBP6
24 March 2024
23andMe Commences Early-Stage Clinical Evaluation of Its Bifunctional Antibody, 23ME-01473, Aimed at ULBP6.
Read →
What is Pharmacovigilance?
"What" Series
2 min read
What is Pharmacovigilance?
24 March 2024
Pharmacovigilance is the science and practice of monitoring the safety and adverse effects of medications that are prescribed, sold, or otherwise in use.
Read →
Nurix Reveals NX-1607, a Novel CBL-B Inhibitor, at ACS Conference
Latest Hotspot
3 min read
Nurix Reveals NX-1607, a Novel CBL-B Inhibitor, at ACS Conference
24 March 2024
Nurix Unveils the Innovation and Molecular Configuration of Pioneering CBL-B Suppressant NX-1607 during the ACS Conference.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Fluticasone Propionate
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Fluticasone Propionate
24 March 2024
Fluticasone Propionate, a small molecule drug, targets the glucocorticoid receptor and acts as an agonist.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.